Jan 26 (Reuters) - AstraZeneca Plc:
* PT010 DEMONSTRATES SIGNIFICANT IMPROVEMENT IN 8 OUT OF NINE LUNG FUNCTION PRIMARY ENDPOINTS COMPARED WITH DUAL COMBINATION THERAPIES
* THERE WERE NO UNEXPECTED SAFETY OR TOLERABILITY SIGNALS FOR PT010 IDENTIFIED IN TRIAL Source text for Eikon: Further company coverage: